Strength in Numbers: Opportunities for Enhancing the Development of Effective Treatments for Type 1 Diabetes—The TrialNet Experience
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
The early to mid-1980s were an inflection point in the history of type 1 diabetes research. Two landmark events occurred: the initiation of immune-based interventions seeking to prevent type 1 diabetes and the presentation of an innovative model describing the disorder’s natural history. Both formed the basis for hundreds of subsequent studies designed to achieve a dramatic therapeutic goal—a means to prevent and/or reverse type 1 diabetes. However, the need to screen large numbers of individuals and prospectively monitor them using immunologic and metabolic tests for extended periods of time suggested such efforts would require a large collaborative network. Hence, the National Institutes of Health formed the landmark Diabetes Prevention Trial-Type 1 (DPT-1) in the mid-1990s, an effort that led to Type 1 Diabetes TrialNet. TrialNet studies have helped identify novel biomarkers; delineate type 1 diabetes progression, resulting in identification of highly predictable stages defined by the accumulation of autoantibodies (stage 1), dysglycemia (stage 2), and disease meeting clinical criteria for diagnosis (stage 3); and oversee numerous clinical trials aimed at preventing disease progression. Such efforts pave the way for stage-specific intervention trials with improved hope that a means to effectively disrupt the disorder’s development will be identified.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnosis and classification of diabetes mellitus
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s081 · Cited by 5,974
Atkinson, M. A., Eisenbarth, G. S., & Michels, A. W. (2014) · The Lancet · doi:10.1016/s0140-6736(13)60591-7 · Cited by 2,931
Self-citationEisenbarth (1986) · doi:10.1056/nejm198605223142106 · Cited by 1,659 · cited 1×
“The most fundamental concept of the Eisenbarth model— that autoimmunity and b-cell dysfunction precede clinical disease—has been repeatedly demonstrated (4) and has”
BackgroundSeroconversion to multiple islet autoantibodies and risk of progression to diabetes in children
Ziegler, A. G., Rewers, M., Simell, O., Simell, T., Lempainen, J., Steck, A., Winkler, C., Ilonen, J., Veijola, R., Knip, M., et al. (2013) · JAMA · doi:10.1001/jama.2013.6285 · Cited by 1,312
Genetics, pathogenesis and clinical interventions in type 1 diabetes
Bluestone, J. A., Herold, K., & Eisenbarth, G. (2010) · Nature · doi:10.1038/nature08933 · Cited by 1,265
Self-citationInsel, R. A., Dunne, J. L., Atkinson, M. A., Chiang, J. L., Dabelea, D., Gottlieb, P. A., Greenbaum, C. J., Herold, K. C., Krischer, J. P., Lernmark, Å., et al. (2015) · Diabetes Care · doi:10.2337/dc15-1419 · Cited by 1,216 · cited 7×
“1) (8) that serve as a useful guide for future therapeutic interventions.”
BackgroundInfluentialSelf-citationT-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection
McKinney, E. F., Lee, J. C., Jayne, D. R. W., Lyons, P. A., & Smith, K. G. C. (2015) · Nature · doi:10.1038/nature14468 · Cited by 685 · cited 1×
“(72) of chronic viral infections and other autoimmune diseases.”
BackgroundRewers, M., Bugawan, T. L., Norris, J. M., Blair, A., Beaty, B., Hoffman, M., McDuffie, R. S., Hamman, R. F., Klingensmith, G., Eisenbarth, G. S., et al. (1996) · Diabetologia · doi:10.1007/s001250050514 · Cited by 422 · cited 1×
“Unique opportunities are made possible by large programs (such as TrialNet) that identify autoantibody-positive relatives through screening across the age spectrum of 1–45 years (9,10), as well as those testing baby cohorts, such as Diabetes Autoimmunity Study in the Young (DAISY) (11,12), BABYDIAB (13), Type 1 Diabet…”
BackgroundFall in C-Peptide During First 2 Years From Diagnosis
Greenbaum, C. J., Beam, C. A., Boulware, D., Gitelman, S. E., Gottlieb, P. A., Herold, K. C., Lachin, J. M., McGee, P., Palmer, J. P., Pescovitz, M. D., et al. (2012) · Diabetes · doi:10.2337/db11-1538 · Cited by 319
Self-citationOram, R. A., Jones, A. G., Besser, R. E. J., Knight, B. A., Shields, B. M., Brown, R. J., Hattersley, A. T., & McDonald, T. J. (2014) · Diabetologia · doi:10.1007/s00125-013-3067-x · Cited by 298 · cited 1×
“Stage 4 is the postdiagnosis period of long-standing disease, a period that still represents a time to intervene as many individuals continue to maintain detectable levels of C-peptide for many years after diagnosis (38,39).”
Background
Cited by
DiMeglio, L. A., Evans-Molina, C., & Oram, R. A. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31320-5 · Cited by 1,561
Pancreatic β-cells in type 1 and type 2 diabetes mellitus: different pathways to failure
Eizirik, D. L., Pasquali, L., & Cnop, M. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0355-7 · Cited by 854
Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals
Sims, E. K., Bundy, B. N., Stier, K., Serti, E., Lim, N., Long, S. A., Geyer, S. M., Moran, A., Greenbaum, C. J., Evans-Molina, C., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abc8980 · Cited by 377
Self-citationInfluence of Vitamin D on Islet Autoimmunity and Beta-Cell Function in Type 1 Diabetes
Infante, M., Ricordi, C., Sanchez, J., Clare-Salzler, M. J., Padilla, N., Fuenmayor, V., Chavez, C., Alvarez, A., Baidal, D., Alejandro, R., et al. (2019) · Nutrients · doi:10.3390/nu11092185 · Cited by 272
Rheumatoid Arthritis Pathogenesis, Prediction, and Prevention: An Emerging Paradigm Shift
Deane, K. D., & Holers, V. M. (2021) · Arthritis & Rheumatology · doi:10.1002/art.41417 · Cited by 255
Metadata
- Authors
- Greenbaum, C. J., Speake, C., Krischer, J., Buckner, J., Gottlieb, P. A., Schatz, D. A., Herold, K. C., & Atkinson, M. A.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2018-05-16
- Volume
- 67
- Issue
- 7
- Pages
- 1216-1225
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2804333559
- Cited by
- 46
- References
- 24
- FWCI
- 3.05
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Strength in Numbers: Opportunities for Enhancing the Development of Effective Treatments for Type 1 Diabetes—The TrialNet Experience. https://app.cochat.ai/papers/10.2337/db18-0065
- The paper
- Greenbaum, C. J., Speake, C., Krischer, J., Buckner, J., Gottlieb, P. A., Schatz, D. A., Herold, K. C., & Atkinson, M. A. (2018). Strength in Numbers: Opportunities for Enhancing the Development of Effective Treatments for Type 1 Diabetes—The TrialNet Experience. Diabetes. https://doi.org/10.2337/db18-0065
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.